The American Society of Clinical Oncology (ASCO) announced today the 14 practices participating in the 2016 Quality Training Program. The program is designed to train oncology health care providers to investigate and implement data-driven quality improvement and manage clinical and administrative processes and outcomes.
The American Society of Clinical Oncology (ASCO) and CancerLinQ LLC will join Vice President Joe Biden and other leaders in the cancer community for the Cancer Moonshot Summit at Howard University, on June 29, to launch new collaborations and exchange ideas on solving the complexities of cancer care.
The American Society of Clinical Oncology (ASCO) announced today that Bayer and Merck are the most recent companies to sign on to provide study drugs at no cost to patients enrolled in the Targeted Agent and Profiling Utilization Registry (TAPUR) study, joining six other companies in ASCO’s first-ever clinical trial. Since opening on March 14, 2016, 18 participants have enrolled and are receiving study treatment, and 31 more have provided consent and are in, or have completed, the screening process. These numbers continue to grow daily.
CHICAGO – A randomized phase III clinical trial, MA.17R found that postmenopausal women with early breast cancer benefit from extending aromatase inhibitor (AI) therapy with letrozole (Femara) from 5 to 10 years. Following five years of an AI and any duration of prior tamoxifen, women who received letrozole for five additional years had a 34% lower risk of recurrence than those who received placebo. The trial was led by the Canadian Cancer Trials Group with participation from the National Clinical Trials Network.
ASCO announced today that a total of 58 practices in 39 states and the District of Columbia have joined CancerLinQ™, ASCO’s big data initiative to rapidly improve the quality of care for people with cancer. CancerLinQ is already up and running in a number of practices and drawing on approximately three-quarters of a million patient records from across the United States.
CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology, Inc. (ASCO®), has announced a collaborative effort with the Cancer Informatics for Cancer Centers (CI4CC). This initiative will bring the nation’s leading clinical, genomics, and biomedical informaticists, academicians, applied research information technology (IT) professionals, and data scientists together with the oncology community to help improve cancer care.
American Society of Clinical Oncology, Inc. (ASCO®) announced today that the Contemporary Oncology Team of Athens, Greece as part of the new international pilot project, is the first international practice to receive Quality Oncology Practice Initiative (QOPI®) certification through QOPI Certification Program, LLC (QCP).
ALEXANDRIA, Va. – American Society of Clinical Oncology, Inc. (ASCO®) and its wholly-owned subsidiary, QOPI Certification Program, LLC (QCP), announced today that The Doctors Company, the nation’s largest physician-owned medical malpractice insurer, will recognize QOPI® Certification in its rate structure. Physicians participating in practices accredited by QCP’s Quality Oncology Practice Initiative (QOPI®) Certification Program will be eligible for a discount of up to 10% on medical malpractice insurance from The Doctors Company.
ALEXANDRIA, Va. – CancerLinQ LLC announced today that it has completed agreements with 36 oncology practices from around the country to begin implementing CancerLinQ™, the groundbreaking health information technology (HIT) platform that will harness big data analytics to help oncologists rapidly improve high-quality care to patients with cancer. CancerLinQ LLC is a wholly-owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO).
ALEXANDRIA, Va. – The American Society of Clinical Oncology (ASCO) announced today a new certificate program designed for advanced practitioners entering oncology care settings.
ALEXANDRIA, Va. – Debra A. Patt, MD, MPH, MBA, has been named editor-in-chief of the new JCO Clinical Cancer Informatics (JCO CCI), a publication of the American Society of Clinical Oncology (ASCO).
ALEXANDRIA, Va. — The American Society of Clinical Oncology (ASCO) today announced it has begun recruiting patients with advanced cancer for its first-ever clinical trial, the Targeted Agent and Profiling Utilization Registry (TAPUR) study. The trial will evaluate molecularly-targeted cancer drugs and collect data on clinical outcomes to help learn additional uses of these drugs outside of indications already approved by the Food and Drug Administration (FDA). Patients enrolled in the study will have access to these cancer drugs at no cost.
Three Industry Leaders Join the CancerLinQ™ Team to Help Guide Big-Data Initiative
The Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) has received a second $1 million from Susan G. Komen® toward the development of CancerLinQ™, a big data project that aims to rapidly improve the overall quality of cancer care. This donation builds on Komen’s previous support of this initiative.
The American Society of Clinical Oncology (ASCO) announced today the publication of seven articles in its new Journal of Global Oncology (JGO). The first articles for this online-only, open-access journal are now available at www.jgo.org.